Newsroom
Sorted by: Latest
-
FLNC Deadline: Rosen Law Firm Urges Fluence Energy, Inc. (NASDAQ: FLNC) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Fluence Energy, Inc. (NASDAQ: FLNC) between November 29, 2023 and February 10, 2025. Fluence describes itself as a company that “offers energy storage products and solutions, delivery services, recurring operational and maintenance services, and digital applications and solutions for energy storage and other power asse...
-
RC Deadline: Rosen Law Firm Urges Ready Capital Corporation (NYSE: RC) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Ready Capital Corporation (NYSE: RC) between November 7, 2024 and March 2, 2025. Ready Capital describes itself as a real estate finance company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Read...
-
Lead Plaintiff Deadline on May 12, 2025 for GERN Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm
RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against Geron Corporation (“Geron”) (NASDAQ: GERN) on behalf of those who purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is May 12, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Geron losses,...
-
Swimlane Ranks ‘Most Valuable Pioneer’ in SecOps AI
SAN FRANCISCO--(BUSINESS WIRE)--Swimlane, AI hyperautomation for the entire security organization, today announced it has been named the “Most Valuable Pioneer” in AI maturity by QKS Group. In the 2025 QKS AI Maturity Matrix™, Swimlane ranks ahead of seven other vendors for its AI-first productization, advanced vision and agentic AI roadmap. Swimlane is ranked ahead of Palo Alto Networks, Cisco, D3, Tines, Fortinet, Torq and Anomali. “Swimlane is leading the shift toward a new AI-led model for...
-
MRVI Deadline: Rosen Law Firm Urges Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024 and February 24, 2025. Maravai is a life sciences company which provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. For more information, submit a form, email...
-
TFII Deadline: Rosen Law Firm Urges TFI International Inc. (NYSE: TFII) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of TFI International Inc. (NYSE: TFII) between April 26, 2024 and February 19, 2025. TFI International is a transportation and logistics company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that TFI Inter...
-
RKLB Deadline: Rosen Law Firm Urges Rocket Lab USA, Inc. (NASDAQ: RKLB) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Rocket Lab USA, Inc. (NASDAQ: RKLB) between November 12, 2024 and February 25, 2025. Rocket Lab describes itself as a “space company which provides launch services, spacecraft design services, spacecraft components, spacecraft manufacturing and other spacecraft and on-orbit management solutions.” For more information, su...
-
ELF Deadline: Rosen Law Firm Urges e.l.f. Beauty, Inc. (NYSE: ELF) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of e.l.f. Beauty, Inc. (“Elf”) (NYSE: ELF) between November 1, 2023 and November 19, 2024. Elf describes itself as a company that “provides cosmetic and skin care products.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating th...
-
QUBT Deadline: Rosen Law Firm Urges Quantum Computing Inc. (NASDAQ: QUBT) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Quantum Computing Inc. (NASDAQ: QUBT) between March 30, 2020 and January 15, 2025. Quantum Computing describes itself as an “American company that purportedly utilizes non-linear quantum optics to deliver quantum products for high-performance computing applications.” For more information, submit a form, email attorney Ph...
-
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease
BOSTON & HONG KONG--(BUSINESS WIRE)--Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Inno...